Beyond Lantus: Sanofi Signs Diabetes Deal With Wellstat
This article was originally published in The Pink Sheet Daily
For a total deal value of $350 million, Sanofi gains global rights to Wellstat's Phase II first-in-class oral insulin sensitizer.
You may also be interested in...
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.